Inflammation

NEW YORK — At the OSN New York 2019 meeting, Scott Corning, senior vice president of commercial, gives an update on the launch of Dextenza, the dexamethasone-eluting intracanalicular insert indicated for the management of inflammation and pain following ophthalmic surgery.

PHILADELPHIA — Adults with a recent MI were less likely to experience an ischemic CV event over 2 years when assigned the anti-inflammatory gout medication colchicine compared with assignment to placebo, according to new results of the COLCOT trial presented at the American Heart Association Scientific Sessions.

The implementation of a novel central-line insertion site assessment score reduced the prevalence of lines with local inflammation or infections, ensured timely response to localized symptoms and reduce central line dwell time at a hospital in California, researchers reported.

ATLANTA — Methotrexate significantly reduced the progression of joint damage among patients with erosive hand osteoarthritis, but demonstrated no significant improvement in pain or function over placebo, according to a presentation at the 2019 ACR/ARP Annual Meeting.

Gilead Sciences announced a strategic collaboration with Glympse Bio for clinical development of nonalcoholic steatohepatitis therapy, according to a press release.

The FDA granted fast track designation to Terns Pharmaceuticals for TERN-101, an investigational farnesoid X receptor being evaluated for nonalcoholic steatohepatitis, according to a press release.

Preservation of residual kidney function reduces morbidity, improves survival and offers other benefits to patients with ESKD. However, more study is needed to understand the mechanisms of residual kidney function along with methods and treatments that can successfully extend preservation, according to a recently published study.

SAN FRANCISCO — For children with uveitic cataract, the timing of surgery and the decision of whether or not to implant an IOL are paramount for successful management, according to a speaker here.

SAN FRANCISCO — Surgeons have many options for controlling pain and inflammation following refractive surgery, William B. Trattler, MD, said in a presentation at Refractive Subspecialty Day at the American Academy of Ophthalmology annual meeting.

The first patient has been dosed in a phase 2b clinical trial of OCS-01 for the treatment of inflammation and pain after cataract surgery, Oculis announced in a press release.